First human tests begin for new drug candidate
NCT ID NCT06698926
Summary
This early-stage study tested a new oral drug called ABBV-CLS-616 in healthy volunteers for the first time. Researchers wanted to understand how safe the drug is, how well people tolerate it, and how the body processes it. The study involved 110 healthy participants and examined different doses, food effects, and potential drug interactions.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Acpru /Id# 270532
Grayslake, Illinois, 60030, United States
Conditions
Explore the condition pages connected to this study.